Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes

Carlos Gonzalez-Quesada, Nikolaos G. Frangogiannis

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalCurrent Atherosclerosis Reports
Volume11
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Chemokine CCL2
Acute Coronary Syndrome
Biomarkers
Blood Proteins
CC Chemokines
Atherosclerotic Plaques

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes. / Gonzalez-Quesada, Carlos; Frangogiannis, Nikolaos G.

In: Current Atherosclerosis Reports, Vol. 11, No. 2, 2009, p. 131-138.

Research output: Contribution to journalArticle

@article{7c7b47dfef064db7b7e53c308926d7a1,
title = "Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes",
abstract = "The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.",
author = "Carlos Gonzalez-Quesada and Frangogiannis, {Nikolaos G.}",
year = "2009",
doi = "10.1007/s11883-009-0021-y",
language = "English (US)",
volume = "11",
pages = "131--138",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "2",

}

TY - JOUR

T1 - Monocyte chemoattractant protein-1/CCL2 as a biomarker in acute coronary syndromes

AU - Gonzalez-Quesada, Carlos

AU - Frangogiannis, Nikolaos G.

PY - 2009

Y1 - 2009

N2 - The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.

AB - The CC chemokine monocyte chemoattractant protein (MCP)-1/CCL2 is involved in the formation, progression, and destabilization of atheromatous plaques and plays an essential role in postinfarction remodeling. These properties generated significant interest in the potential significance of MCP-1 as a biomarker in acute coronary syndromes (ACS). Emerging evidence suggests that MCP-1 plasma levels have prognostic value in the acute and chronic phase following ACS, providing information independent of standard clinical variables. The mechanisms responsible for adverse prognosis in patients with elevated plasma MCP-1 following ACS remain unknown. High plasma MCP-1 levels may reflect a higher burden of atherosclerotic disease, may exert prothrombotic effects resulting in recurrent coronary events, or may identify patients who mount a more intense cardiac inflammatory reaction following a coronary event, resulting in enhanced adverse remodeling. Beyond its prognostic significance, the MCP-1 axis may be an attractive target for therapy in patients with ACS.

UR - http://www.scopus.com/inward/record.url?scp=60849117539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849117539&partnerID=8YFLogxK

U2 - 10.1007/s11883-009-0021-y

DO - 10.1007/s11883-009-0021-y

M3 - Article

VL - 11

SP - 131

EP - 138

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 2

ER -